<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600821</url>
  </required_header>
  <id_info>
    <org_study_id>A4061030</org_study_id>
    <nct_id>NCT00600821</nct_id>
  </id_info>
  <brief_title>A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.</brief_title>
  <official_title>Randomized Phase 2 Trial Of AG013736 Or Bevacizumab In Combination With Paclitaxel And Carboplatin As First Line Treatment For Patients With Advanced Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if the addition of AG-013736 to chemotherapy is beneficial in patients with
      advanced lung cancer who have not been previously treated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years</time_frame>
    <description>Time in months from start of study treatment to first randomization date of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was &quot;Death&quot;).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline, every 6 weeks until death or bimonthly after final study visit (up to 2.75 years)</time_frame>
    <description>Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the first randomization date plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Objective Response (OR)</measure>
    <time_frame>Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years</time_frame>
    <description>OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR: disappearance of all lesions (target and/or non target) and no appearance of new lesions. PR: at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, without progression of non target lesions and no appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years</time_frame>
    <description>Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetic (PK) Analysis for Axitinib (AG-013736)</measure>
    <time_frame>Pre-dose, 1 to 2 hours post-dose on Cycle 2 of Day 1 and Cycle 3 of Day 1</time_frame>
    <description>Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score</measure>
    <time_frame>Day (D) 1 of every cycle (C) then every 3 weeks until final study visit (up to 2.75 years)</time_frame>
    <description>EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhoea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score</measure>
    <time_frame>Day 1 of every cycle then every 3 weeks until final study visit (up to 2.75 years)</time_frame>
    <description>QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnoea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by Ribonucleic Acid (RNA) Expression Profile in Whole Blood</measure>
    <time_frame>Baseline, C1 D1, C1 D15, C2 D1, C3 D1, C4 D1 and C5 D1</time_frame>
    <description>RNA expression profiles of genes which were associated with tumor growth, angiogenesis and metastases were collected and correlated with efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Endothelial Cells (CEC) in Blood: Total CEC</measure>
    <time_frame>Baseline (C1 D1), C1 D15, C2 D1, C3 D1, C4 D1, C5 D1, C7 D1, C9 D1 and C11 D1</time_frame>
    <description>Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Endothelial Cells (CEC) in Blood</measure>
    <time_frame>Baseline (C1 D1), C1 D15, C2 D1, C3 D1, C4 D1, C5 D1, C7 D1, C9 D1 and C11 D1</time_frame>
    <description>Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Soluble Proteins</measure>
    <time_frame>Baseline, C1D1, C1D15, C2D1, C3D1, C4D1, C5D1, C7D1, C9D1 and C11D1</time_frame>
    <description>Plasma concentrations of soluble proteins (soluble- stem-cell factor receptor (sKIT) vascular endothelial growth factor [VEGF], and vascular endothelial growth factor receptor-2 [VEGFR2], VEGFR3) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma Concentration Change in the Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) Genotype</measure>
    <time_frame>Baseline (Day 1 of Cycle 1)</time_frame>
    <description>UGT1A1 an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab will be administered in combination with carboplatin and paclitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AG-013736 will be administered in combination with carboplatin and paclitaxel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg*min/ml, iv infusion, every 3 weeks.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AG-013736 (axitinib)</intervention_name>
    <description>AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-</description>
    <arm_group_label>A</arm_group_label>
    <other_name>axitinib Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg*min/ml, iv infusion, every 3 weeks.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced non squamous cell, lung cancer

          -  No prior treatment for lung cancer except prior adjuvant therapy if last dose was &gt;12
             months prior to enrollment

        Exclusion Criteria:

          -  Prior therapy for advanced lung cancer

          -  The need for blood-thinners

          -  Coughing up blood
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Mississippi</state>
        <zip>39705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Corinth</city>
        <state>Mississippi</state>
        <zip>38834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Albany</city>
        <state>Mississippi</state>
        <zip>38652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oxford</city>
        <state>Mississippi</state>
        <zip>38655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Southaven</city>
        <state>Mississippi</state>
        <zip>38671</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8590</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 8</city>
        <zip>180 81</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tabor</city>
        <zip>390 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Caen Cedex 05</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pierre-BÃ©nite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-462</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torun</city>
        <zip>87 - 100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mataro</city>
        <state>Barcelona</state>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dundee</city>
        <state>Scotland</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leeds</city>
        <state>Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Surrey</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4061030&amp;StudyName=A%20Study%20Of%20AG-013736%20%28Axitinib%29%20Or%20Bevacizumab%20%28Avastin%29%20In%20Combination%20With%20Paclitaxel%20And%20Carboplatin%20In%20Patients%20With%20Advanced%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <results_first_submitted>April 20, 2012</results_first_submitted>
  <results_first_submitted_qc>April 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 22, 2012</results_first_posted>
  <disposition_first_submitted>February 11, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 11, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 15, 2010</disposition_first_posted>
  <last_update_submitted>October 16, 2013</last_update_submitted>
  <last_update_submitted_qc>October 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Axitinib + Paclitaxel + Carboplatin</title>
          <description>Axitinib (AG-013736) 5 milligram (mg) tablet administered orally twice daily (BID) along with infusion of paclitaxel 200 mg per square meter (mg/m^2) over 3 hours and carboplatin area under the concentration-time curve (AUC) of 6 mg*minute/milliliter (mg*min/mL) infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy.</description>
        </group>
        <group group_id="P2">
          <title>Bevacizumab + Paclitaxel + Carboplatin</title>
          <description>Bevacizumab 15 mg/kilogram (mg/kg) infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m^2 over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Objective progression or relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Axitinib + Paclitaxel + Carboplatin</title>
          <description>Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m^2) over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy.</description>
        </group>
        <group group_id="B2">
          <title>Bevacizumab + Paclitaxel + Carboplatin</title>
          <description>Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m^2 over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="118"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 to 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Time in months from start of study treatment to first randomization date of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was &quot;Death&quot;).</description>
        <time_frame>Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years</time_frame>
        <population>Intent-to-treat (ITT) population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib + Paclitaxel + Carboplatin</title>
            <description>Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m^2) over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + Paclitaxel + Carboplatin</title>
            <description>Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m^2 over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>Time in months from start of study treatment to first randomization date of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was &quot;Death&quot;).</description>
          <population>Intent-to-treat (ITT) population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="4.1" upper_limit="7.5"/>
                    <measurement group_id="O2" value="6.1" lower_limit="4.2" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Differences in PFS between treatment arms was analyzed by 1-sided log rank test, stratified by gender and prior adjuvant therapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.639</p_value>
            <p_value_desc>One-sided log-rank test at alpha = 0.20 significance level was used.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.093</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.679</ci_lower_limit>
            <ci_upper_limit>1.761</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the first randomization date plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).</description>
        <time_frame>Baseline, every 6 weeks until death or bimonthly after final study visit (up to 2.75 years)</time_frame>
        <population>ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib + Paclitaxel + Carboplatin</title>
            <description>Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m^2) over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + Paclitaxel + Carboplatin</title>
            <description>Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m^2 over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the first randomization date plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).</description>
          <population>ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="7.5" upper_limit="16.4"/>
                    <measurement group_id="O2" value="13.3" lower_limit="10.4" upper_limit="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Differences in OS between treatment arms was analyzed by 1-sided log rank test, stratified by gender and prior adjuvant therapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.699</p_value>
            <p_value_desc>One-sided log-rank test at alpha = 0.20 significance level was used.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.117</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.739</ci_lower_limit>
            <ci_upper_limit>1.689</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Objective Response (OR)</title>
        <description>OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR: disappearance of all lesions (target and/or non target) and no appearance of new lesions. PR: at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, without progression of non target lesions and no appearance of new lesions.</description>
        <time_frame>Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years</time_frame>
        <population>ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib + Paclitaxel + Carboplatin</title>
            <description>Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m^2) over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + Paclitaxel + Carboplatin</title>
            <description>Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m^2 over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Objective Response (OR)</title>
          <description>OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR: disappearance of all lesions (target and/or non target) and no appearance of new lesions. PR: at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, without progression of non target lesions and no appearance of new lesions.</description>
          <population>ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" lower_limit="18.1" upper_limit="42.7"/>
                    <measurement group_id="O2" value="43.3" lower_limit="30.6" upper_limit="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated using 1-sided Cochran-Mantel-Haenszel test stratified by gender and prior adjuvant therapy. Risk ratio in comparison to the Bevacizumab group was calculated assuming all other factors as constant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9422</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.676</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.412</ci_lower_limit>
            <ci_upper_limit>1.107</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DR)</title>
        <description>Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.</description>
        <time_frame>Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years</time_frame>
        <population>DR was calculated for the subgroup of participants from the ITT population, with a confirmed objective tumor response (CR or PR).</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib + Paclitaxel + Carboplatin</title>
            <description>Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m^2) over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + Paclitaxel + Carboplatin</title>
            <description>Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m^2 over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DR)</title>
          <description>Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.</description>
          <population>DR was calculated for the subgroup of participants from the ITT population, with a confirmed objective tumor response (CR or PR).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="4.2" upper_limit="6.7"/>
                    <measurement group_id="O2" value="7.0" lower_limit="4.8" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population Pharmacokinetic (PK) Analysis for Axitinib (AG-013736)</title>
        <description>Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.</description>
        <time_frame>Pre-dose, 1 to 2 hours post-dose on Cycle 2 of Day 1 and Cycle 3 of Day 1</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score</title>
        <description>EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhoea, and financial difficulties). Most questions used 4- point scale (1 âNot at Allâ to 4 âVery Muchâ); 2 questions used 7-point scale (1 âVery Poorâ to 7 âExcellentâ). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.</description>
        <time_frame>Day (D) 1 of every cycle (C) then every 3 weeks until final study visit (up to 2.75 years)</time_frame>
        <population>ITT population included participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or different drug from which they were randomized. ânâ signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib + Paclitaxel + Carboplatin</title>
            <description>Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m^2) over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + Paclitaxel + Carboplatin</title>
            <description>Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m^2 over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score</title>
          <description>EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhoea, and financial difficulties). Most questions used 4- point scale (1 âNot at Allâ to 4 âVery Muchâ); 2 questions used 7-point scale (1 âVery Poorâ to 7 âExcellentâ). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.</description>
          <population>ITT population included participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or different drug from which they were randomized. ânâ signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning (PF): Baseline (n=58, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.29" spread="22.04"/>
                    <measurement group_id="O2" value="75.00" spread="22.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF: C2 D1 (n=51, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.45" spread="23.48"/>
                    <measurement group_id="O2" value="75.47" spread="20.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF: C3 D1 (n=45, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.78" spread="24.40"/>
                    <measurement group_id="O2" value="78.16" spread="18.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.88" spread="20.01"/>
                    <measurement group_id="O2" value="73.78" spread="19.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF: C5 D1 (n=34, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.18" spread="24.09"/>
                    <measurement group_id="O2" value="75.09" spread="16.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF: C6 D1 (n=31, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.86" spread="19.17"/>
                    <measurement group_id="O2" value="73.94" spread="18.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF: C7 D1 (n=27, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.42" spread="22.15"/>
                    <measurement group_id="O2" value="74.89" spread="18.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF: C8 D1 (n=22, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.27" spread="22.44"/>
                    <measurement group_id="O2" value="77.14" spread="18.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.30" spread="27.77"/>
                    <measurement group_id="O2" value="74.57" spread="19.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.63" spread="25.36"/>
                    <measurement group_id="O2" value="81.33" spread="14.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.67" spread="23.58"/>
                    <measurement group_id="O2" value="78.25" spread="16.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.33" spread="20.86"/>
                    <measurement group_id="O2" value="78.43" spread="19.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" spread="25.94"/>
                    <measurement group_id="O2" value="79.05" spread="21.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF: End of treatment (EOT) (n=27, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.96" spread="21.11"/>
                    <measurement group_id="O2" value="64.91" spread="24.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning: Baseline (n=58, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.92" spread="31.15"/>
                    <measurement group_id="O2" value="60.63" spread="31.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning: C2 D1 (n=51, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.38" spread="31.98"/>
                    <measurement group_id="O2" value="65.41" spread="29.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning: C3 D1 (n=45, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.15" spread="34.01"/>
                    <measurement group_id="O2" value="70.92" spread="28.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.12" spread="26.49"/>
                    <measurement group_id="O2" value="67.36" spread="25.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning: C5 D1 (n=34, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.35" spread="29.64"/>
                    <measurement group_id="O2" value="66.23" spread="29.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning: C6 D1 (n=31, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.90" spread="30.34"/>
                    <measurement group_id="O2" value="67.68" spread="29.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning: C7 D1 (n=28, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.36" spread="32.41"/>
                    <measurement group_id="O2" value="63.89" spread="27.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning: C8 D1 (n=22, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.15" spread="29.05"/>
                    <measurement group_id="O2" value="71.43" spread="19.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.89" spread="37.60"/>
                    <measurement group_id="O2" value="70.29" spread="18.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" spread="28.87"/>
                    <measurement group_id="O2" value="70.83" spread="20.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00" spread="29.41"/>
                    <measurement group_id="O2" value="71.93" spread="21.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00" spread="21.15"/>
                    <measurement group_id="O2" value="70.59" spread="21.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.50" spread="33.04"/>
                    <measurement group_id="O2" value="80.95" spread="20.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning: EOT (n=27, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.41" spread="32.47"/>
                    <measurement group_id="O2" value="57.90" spread="31.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning: Baseline (n=57, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.74" spread="23.45"/>
                    <measurement group_id="O2" value="63.74" spread="27.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning: C2 D1 (n=50, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.33" spread="21.76"/>
                    <measurement group_id="O2" value="73.64" spread="22.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning: C3 D1 (n=45, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.19" spread="21.36"/>
                    <measurement group_id="O2" value="78.76" spread="20.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.75" spread="20.17"/>
                    <measurement group_id="O2" value="76.04" spread="23.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning: C5 D1 (n=32, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.60" spread="18.38"/>
                    <measurement group_id="O2" value="78.51" spread="21.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning: C6 D1 (n=29, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.74" spread="18.97"/>
                    <measurement group_id="O2" value="77.35" spread="23.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning: C7 D1 (n=28, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.57" spread="22.62"/>
                    <measurement group_id="O2" value="79.45" spread="20.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning: C8 D1 (n=22, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.65" spread="19.14"/>
                    <measurement group_id="O2" value="81.25" spread="18.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.07" spread="19.78"/>
                    <measurement group_id="O2" value="78.50" spread="23.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.94" spread="18.85"/>
                    <measurement group_id="O2" value="78.33" spread="13.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.00" spread="21.32"/>
                    <measurement group_id="O2" value="82.46" spread="18.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.17" spread="27.90"/>
                    <measurement group_id="O2" value="77.45" spread="20.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.08" spread="22.60"/>
                    <measurement group_id="O2" value="83.93" spread="14.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning: EOT (n=27, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.52" spread="26.39"/>
                    <measurement group_id="O2" value="70.18" spread="25.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning: Baseline (n=57, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.12" spread="24.28"/>
                    <measurement group_id="O2" value="83.33" spread="19.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning: C2 D1 (n=50, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.00" spread="20.47"/>
                    <measurement group_id="O2" value="84.28" spread="21.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning: C3 D1 (n=45, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.19" spread="22.81"/>
                    <measurement group_id="O2" value="85.42" spread="20.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.68" spread="18.99"/>
                    <measurement group_id="O2" value="82.64" spread="20.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning: C5 D1 (n=32, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.37" spread="19.83"/>
                    <measurement group_id="O2" value="83.33" spread="24.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning: C6 D1 (n=29, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.78" spread="18.03"/>
                    <measurement group_id="O2" value="81.25" spread="21.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning: C7 D1 (n=28, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.76" spread="19.43"/>
                    <measurement group_id="O2" value="85.56" spread="18.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning: C8 D1 (n=22, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.39" spread="17.48"/>
                    <measurement group_id="O2" value="88.69" spread="17.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.26" spread="15.63"/>
                    <measurement group_id="O2" value="86.23" spread="20.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.23" spread="12.86"/>
                    <measurement group_id="O2" value="90.00" spread="13.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.22" spread="18.33"/>
                    <measurement group_id="O2" value="85.96" spread="18.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.00" spread="14.05"/>
                    <measurement group_id="O2" value="87.25" spread="20.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.42" spread="13.91"/>
                    <measurement group_id="O2" value="95.24" spread="12.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning: EOT (n=27, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.78" spread="23.57"/>
                    <measurement group_id="O2" value="78.95" spread="22.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: Baseline (n=57, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.35" spread="27.59"/>
                    <measurement group_id="O2" value="65.50" spread="32.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: C2 D1 (n=50, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.67" spread="30.06"/>
                    <measurement group_id="O2" value="75.32" spread="25.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: C3 D1 (n=45, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.11" spread="27.62"/>
                    <measurement group_id="O2" value="74.65" spread="24.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.42" spread="24.99"/>
                    <measurement group_id="O2" value="71.53" spread="29.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: C5 D1 (n=32, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.10" spread="26.22"/>
                    <measurement group_id="O2" value="75.88" spread="27.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: C6 D1 (n=29, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.11" spread="26.49"/>
                    <measurement group_id="O2" value="71.88" spread="26.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: C7 D1 (n=28, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.88" spread="32.50"/>
                    <measurement group_id="O2" value="72.22" spread="23.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: C8 D1 (n=22, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.97" spread="24.87"/>
                    <measurement group_id="O2" value="72.02" spread="24.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.07" spread="29.83"/>
                    <measurement group_id="O2" value="81.16" spread="16.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.55" spread="32.24"/>
                    <measurement group_id="O2" value="79.17" spread="20.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" spread="28.17"/>
                    <measurement group_id="O2" value="78.95" spread="16.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.67" spread="20.86"/>
                    <measurement group_id="O2" value="80.39" spread="20.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.25" spread="28.08"/>
                    <measurement group_id="O2" value="80.95" spread="18.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: EOT (n=27, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.14" spread="26.03"/>
                    <measurement group_id="O2" value="65.79" spread="26.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Baseline (n=57, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.45" spread="23.94"/>
                    <measurement group_id="O2" value="38.89" spread="28.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: C2 D1 (n=51, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.57" spread="21.98"/>
                    <measurement group_id="O2" value="36.48" spread="25.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: C3 D1 (n=45, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.41" spread="22.77"/>
                    <measurement group_id="O2" value="33.80" spread="19.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.34" spread="19.22"/>
                    <measurement group_id="O2" value="37.85" spread="19.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: C5 D1 (n=34, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.61" spread="21.73"/>
                    <measurement group_id="O2" value="36.84" spread="22.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: C6 D1 (n=31, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.16" spread="23.65"/>
                    <measurement group_id="O2" value="33.50" spread="21.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: C7 D1 (n=28, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.82" spread="27.27"/>
                    <measurement group_id="O2" value="40.74" spread="21.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: C8 D1 (n=22, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.95" spread="24.84"/>
                    <measurement group_id="O2" value="32.14" spread="20.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.12" spread="29.80"/>
                    <measurement group_id="O2" value="28.98" spread="20.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.83" spread="25.62"/>
                    <measurement group_id="O2" value="30.00" spread="19.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.78" spread="32.52"/>
                    <measurement group_id="O2" value="28.07" spread="14.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.78" spread="19.74"/>
                    <measurement group_id="O2" value="29.41" spread="18.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00" spread="24.49"/>
                    <measurement group_id="O2" value="26.19" spread="22.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: EOT (n=27, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.03" spread="24.51"/>
                    <measurement group_id="O2" value="43.13" spread="27.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting: Baseline (n=57, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.77" spread="17.85"/>
                    <measurement group_id="O2" value="9.89" spread="21.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting: C2 D1 (n=51, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.19" spread="13.02"/>
                    <measurement group_id="O2" value="5.35" spread="12.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting: C3 D1 (n=45, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.11" spread="17.77"/>
                    <measurement group_id="O2" value="5.67" spread="11.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.81" spread="16.77"/>
                    <measurement group_id="O2" value="7.29" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting: C5 D1 (n=34, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.24" spread="21.63"/>
                    <measurement group_id="O2" value="7.46" spread="14.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting: C6 D1 (n=31, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.44" spread="21.26"/>
                    <measurement group_id="O2" value="10.61" spread="17.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting: C7 D1 (n=28, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.48" spread="22.65"/>
                    <measurement group_id="O2" value="9.44" spread="14.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting: C8 D1 (n=22, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.40" spread="22.00"/>
                    <measurement group_id="O2" value="5.95" spread="12.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" spread="13.06"/>
                    <measurement group_id="O2" value="5.07" spread="20.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.77" spread="15.33"/>
                    <measurement group_id="O2" value="8.33" spread="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.45" spread="17.67"/>
                    <measurement group_id="O2" value="5.26" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.00" spread="16.57"/>
                    <measurement group_id="O2" value="6.68" spread="14.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.50" spread="17.25"/>
                    <measurement group_id="O2" value="5.95" spread="14.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting: EOT (n=27, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.05" spread="22.40"/>
                    <measurement group_id="O2" value="7.90" spread="14.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Baseline (n=57, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.29" spread="31.82"/>
                    <measurement group_id="O2" value="35.31" spread="30.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: C2 D1 (n=51, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.74" spread="29.87"/>
                    <measurement group_id="O2" value="28.30" spread="29.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: C3 D1 (n=45, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.00" spread="27.43"/>
                    <measurement group_id="O2" value="18.75" spread="18.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.58" spread="18.62"/>
                    <measurement group_id="O2" value="25.35" spread="27.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: C5 D1 (n=34, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" spread="18.91"/>
                    <measurement group_id="O2" value="24.12" spread="24.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: C6 D1 (n=31, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.18" spread="18.63"/>
                    <measurement group_id="O2" value="25.25" spread="28.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: C7 D1 (n=28, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.57" spread="28.99"/>
                    <measurement group_id="O2" value="27.22" spread="26.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: C8 D1 (n=22, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.03" spread="25.91"/>
                    <measurement group_id="O2" value="22.62" spread="23.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" spread="22.14"/>
                    <measurement group_id="O2" value="27.54" spread="31.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.39" spread="26.51"/>
                    <measurement group_id="O2" value="24.17" spread="24.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.33" spread="28.03"/>
                    <measurement group_id="O2" value="18.42" spread="21.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.00" spread="21.45"/>
                    <measurement group_id="O2" value="23.53" spread="29.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.42" spread="24.30"/>
                    <measurement group_id="O2" value="16.67" spread="21.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: EOT (n=27, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.27" spread="33.27"/>
                    <measurement group_id="O2" value="34.65" spread="30.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: Baseline (n=56, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.74" spread="30.15"/>
                    <measurement group_id="O2" value="36.21" spread="33.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C2 D1 (n=51, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.03" spread="28.25"/>
                    <measurement group_id="O2" value="24.36" spread="31.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C3 D1 (n=45, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.52" spread="28.39"/>
                    <measurement group_id="O2" value="19.15" spread="23.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" spread="30.43"/>
                    <measurement group_id="O2" value="21.53" spread="25.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C5 D1 (n=34, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.27" spread="33.20"/>
                    <measurement group_id="O2" value="23.68" spread="27.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C6 D1 (n=31, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.56" spread="31.45"/>
                    <measurement group_id="O2" value="20.20" spread="23.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C7 D1 (n=28, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.09" spread="31.05"/>
                    <measurement group_id="O2" value="21.11" spread="20.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C8 D1 (n=22, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.27" spread="28.43"/>
                    <measurement group_id="O2" value="16.67" spread="19.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.93" spread="33.44"/>
                    <measurement group_id="O2" value="21.74" spread="21.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.45" spread="31.70"/>
                    <measurement group_id="O2" value="18.33" spread="17.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.78" spread="33.01"/>
                    <measurement group_id="O2" value="17.54" spread="23.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.33" spread="27.44"/>
                    <measurement group_id="O2" value="21.57" spread="23.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.50" spread="37.53"/>
                    <measurement group_id="O2" value="19.05" spread="17.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: EOT (n=27, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.80" spread="27.62"/>
                    <measurement group_id="O2" value="33.33" spread="33.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia: Baseline (n=57, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.20" spread="33.19"/>
                    <measurement group_id="O2" value="37.93" spread="31.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia: C2 D1 (n=51, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.60" spread="36.06"/>
                    <measurement group_id="O2" value="28.30" spread="33.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia: C3 D1 (n=45, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.37" spread="33.20"/>
                    <measurement group_id="O2" value="29.08" spread="33.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.32" spread="26.81"/>
                    <measurement group_id="O2" value="27.08" spread="28.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia: C5 D1 (n=34, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.43" spread="24.80"/>
                    <measurement group_id="O2" value="23.68" spread="31.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia: C6 D1 (n=31, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.73" spread="25.77"/>
                    <measurement group_id="O2" value="24.24" spread="29.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia: C7 D1 (n=28, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.81" spread="28.48"/>
                    <measurement group_id="O2" value="25.55" spread="24.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia: C8 D1 (n=22, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.21" spread="26.32"/>
                    <measurement group_id="O2" value="19.05" spread="23.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.93" spread="31.43"/>
                    <measurement group_id="O2" value="23.19" spread="27.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.45" spread="26.97"/>
                    <measurement group_id="O2" value="20.00" spread="25.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" spread="28.17"/>
                    <measurement group_id="O2" value="22.81" spread="24.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.67" spread="21.08"/>
                    <measurement group_id="O2" value="23.53" spread="28.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.50" spread="17.25"/>
                    <measurement group_id="O2" value="16.67" spread="17.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia: EOT (n=27, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.39" spread="27.28"/>
                    <measurement group_id="O2" value="36.94" spread="30.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite: Baseline (n=57, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.82" spread="28.65"/>
                    <measurement group_id="O2" value="31.64" spread="34.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite: C2 D1 (n=51, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.53" spread="26.91"/>
                    <measurement group_id="O2" value="20.75" spread="29.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite: C3 D1 (n=44, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" spread="32.94"/>
                    <measurement group_id="O2" value="17.02" spread="25.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.13" spread="26.22"/>
                    <measurement group_id="O2" value="23.61" spread="27.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite: C5 D1 (n=34, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.39" spread="33.20"/>
                    <measurement group_id="O2" value="21.05" spread="29.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite: C6 D1 (n=31, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.96" spread="31.15"/>
                    <measurement group_id="O2" value="23.23" spread="26.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite: C7 D1 (n=28, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.29" spread="34.01"/>
                    <measurement group_id="O2" value="24.44" spread="23.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite: C8 D1 (n=22, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.36" spread="28.93"/>
                    <measurement group_id="O2" value="19.05" spread="21.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.48" spread="26.75"/>
                    <measurement group_id="O2" value="13.04" spread="24.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.22" spread="31.70"/>
                    <measurement group_id="O2" value="20.00" spread="25.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" spread="35.64"/>
                    <measurement group_id="O2" value="15.79" spread="17.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="23.57"/>
                    <measurement group_id="O2" value="23.53" spread="30.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.17" spread="21.36"/>
                    <measurement group_id="O2" value="16.67" spread="28.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite: EOT (n=27, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.51" spread="34.64"/>
                    <measurement group_id="O2" value="37.72" spread="33.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation: Baseline (n=56, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.48" spread="23.75"/>
                    <measurement group_id="O2" value="21.05" spread="31.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation: C2 D1 (n=50, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.33" spread="28.38"/>
                    <measurement group_id="O2" value="20.13" spread="26.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation: C3 D1 (n=45, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.52" spread="24.16"/>
                    <measurement group_id="O2" value="14.89" spread="23.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation: C4 D1 (n=36, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.52" spread="26.96"/>
                    <measurement group_id="O2" value="13.19" spread="21.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation: C5 D1 (n=32, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.75" spread="22.30"/>
                    <measurement group_id="O2" value="21.05" spread="27.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation: C6 D1 (n=28, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.62" spread="25.75"/>
                    <measurement group_id="O2" value="19.19" spread="28.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation: C7 D1 (n=28, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" spread="26.64"/>
                    <measurement group_id="O2" value="7.78" spread="14.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation: C8 D1 (n=22, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.70" spread="19.68"/>
                    <measurement group_id="O2" value="2.38" spread="8.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" spread="19.15"/>
                    <measurement group_id="O2" value="5.80" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.65" spread="20.81"/>
                    <measurement group_id="O2" value="5.00" spread="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.22" spread="20.57"/>
                    <measurement group_id="O2" value="8.77" spread="18.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00" spread="23.31"/>
                    <measurement group_id="O2" value="5.88" spread="17.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="25.20"/>
                    <measurement group_id="O2" value="4.76" spread="12.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation: EOT (n=27, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.99" spread="29.45"/>
                    <measurement group_id="O2" value="14.03" spread="24.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea: Baseline (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" spread="17.45"/>
                    <measurement group_id="O2" value="5.85" spread="14.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea: C2 D1 (n=50, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.33" spread="17.31"/>
                    <measurement group_id="O2" value="10.06" spread="21.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea: C3 D1 (n=45, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.55" spread="18.26"/>
                    <measurement group_id="O2" value="9.72" spread="21.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea: C4 D1 (n=37, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.51" spread="19.97"/>
                    <measurement group_id="O2" value="5.67" spread="12.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea: C5 D1 (n=32, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.92" spread="32.17"/>
                    <measurement group_id="O2" value="7.89" spread="18.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea: C6 D1 (n=29, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.84" spread="28.56"/>
                    <measurement group_id="O2" value="10.42" spread="19.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea: C7 D1 (n=28, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="26.45"/>
                    <measurement group_id="O2" value="11.11" spread="15.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea: C8 D1 (n=22, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.24" spread="31.17"/>
                    <measurement group_id="O2" value="4.76" spread="11.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.78" spread="28.58"/>
                    <measurement group_id="O2" value="5.80" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.53" spread="30.65"/>
                    <measurement group_id="O2" value="10.00" spread="19.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.11" spread="34.43"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.33" spread="16.10"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" spread="25.20"/>
                    <measurement group_id="O2" value="7.14" spread="14.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea: EOT (n=27, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.46" spread="28.96"/>
                    <measurement group_id="O2" value="3.51" spread="12.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties: Baseline (n=56, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.62" spread="31.85"/>
                    <measurement group_id="O2" value="21.64" spread="27.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties: C2 D1 (n=49, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.77" spread="31.59"/>
                    <measurement group_id="O2" value="20.12" spread="27.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties: C3 D1 (n=45, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.93" spread="30.89"/>
                    <measurement group_id="O2" value="18.05" spread="23.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.62" spread="27.46"/>
                    <measurement group_id="O2" value="20.83" spread="30.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties: C5 D1 (n=32, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.04" spread="30.21"/>
                    <measurement group_id="O2" value="21.05" spread="28.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties: C6 D1 (n=29, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.44" spread="28.70"/>
                    <measurement group_id="O2" value="20.83" spread="29.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties: C7 D1 (n=28, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.19" spread="31.89"/>
                    <measurement group_id="O2" value="26.67" spread="30.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties: C8 D1 (n=21, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.57" spread="35.41"/>
                    <measurement group_id="O2" value="21.43" spread="32.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.78" spread="36.60"/>
                    <measurement group_id="O2" value="17.39" spread="29.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties: C10 D1 (n=17, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.45" spread="33.82"/>
                    <measurement group_id="O2" value="24.56" spread="33.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00" spread="30.34"/>
                    <measurement group_id="O2" value="19.30" spread="27.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33" spread="23.31"/>
                    <measurement group_id="O2" value="17.65" spread="26.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.83" spread="35.36"/>
                    <measurement group_id="O2" value="16.67" spread="28.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties: EOT (n=27, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.46" spread="27.45"/>
                    <measurement group_id="O2" value="28.83" spread="32.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL: Baseline (n=57, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.22" spread="22.03"/>
                    <measurement group_id="O2" value="54.97" spread="21.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL: C2 D1 (n=49, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.16" spread="20.38"/>
                    <measurement group_id="O2" value="59.59" spread="17.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL: C3 D1 (n=45, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.67" spread="20.07"/>
                    <measurement group_id="O2" value="59.72" spread="16.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL: C4 D1 (n=37, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.21" spread="18.02"/>
                    <measurement group_id="O2" value="57.80" spread="18.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL: C5 D1 (n=32, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.07" spread="21.94"/>
                    <measurement group_id="O2" value="61.84" spread="17.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL: C6 D1 (n=29, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.45" spread="17.75"/>
                    <measurement group_id="O2" value="60.94" spread="17.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL: C7 D1 (n=28, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.65" spread="20.17"/>
                    <measurement group_id="O2" value="58.61" spread="15.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL: C8 D1 (n=22, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.82" spread="17.18"/>
                    <measurement group_id="O2" value="60.71" spread="15.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL: C9 D1 (n=18, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.48" spread="23.14"/>
                    <measurement group_id="O2" value="64.40" spread="15.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.39" spread="17.91"/>
                    <measurement group_id="O2" value="62.50" spread="14.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.78" spread="19.02"/>
                    <measurement group_id="O2" value="63.60" spread="15.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.17" spread="19.35"/>
                    <measurement group_id="O2" value="63.73" spread="12.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.13" spread="19.89"/>
                    <measurement group_id="O2" value="58.33" spread="15.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL: EOT (n=27, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.38" spread="20.92"/>
                    <measurement group_id="O2" value="50.22" spread="21.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score</title>
        <description>QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnoea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.</description>
        <time_frame>Day 1 of every cycle then every 3 weeks until final study visit (up to 2.75 years)</time_frame>
        <population>ITT population included participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or different drug from which they were randomized. ânâ signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib + Paclitaxel + Carboplatin</title>
            <description>Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m^2) over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + Paclitaxel + Carboplatin</title>
            <description>Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m^2 over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score</title>
          <description>QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnoea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.</description>
          <population>ITT population included participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or different drug from which they were randomized. ânâ signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cough: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.50" spread="31.18"/>
                    <measurement group_id="O2" value="38.42" spread="24.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: C2 D1 (n=50, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.67" spread="24.13"/>
                    <measurement group_id="O2" value="30.19" spread="20.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: C3 D1 (n=46, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.98" spread="25.92"/>
                    <measurement group_id="O2" value="28.37" spread="23.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.73" spread="25.80"/>
                    <measurement group_id="O2" value="27.08" spread="20.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: C5 D1 (n=33, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.22" spread="18.00"/>
                    <measurement group_id="O2" value="28.07" spread="23.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: C6 D1 (n=29, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.44" spread="24.20"/>
                    <measurement group_id="O2" value="26.26" spread="23.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: C7 D1 (n=28, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" spread="21.52"/>
                    <measurement group_id="O2" value="25.29" spread="24.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: C8 D1 (n=22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.21" spread="19.37"/>
                    <measurement group_id="O2" value="19.75" spread="21.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.37" spread="20.26"/>
                    <measurement group_id="O2" value="24.64" spread="25.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.53" spread="25.73"/>
                    <measurement group_id="O2" value="21.67" spread="22.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.44" spread="23.46"/>
                    <measurement group_id="O2" value="26.31" spread="23.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.66" spread="14.05"/>
                    <measurement group_id="O2" value="29.41" spread="30.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" spread="25.20"/>
                    <measurement group_id="O2" value="21.43" spread="21.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: End of treatment (EOT) (n=26, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" spread="21.08"/>
                    <measurement group_id="O2" value="33.33" spread="29.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="11.51"/>
                    <measurement group_id="O2" value="3.39" spread="10.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis: C2 D1 (n=50, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="9.13"/>
                    <measurement group_id="O2" value="1.89" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis: C3 D1 (n=44, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="5.02"/>
                    <measurement group_id="O2" value="5.67" spread="14.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis: C4 D1 (n=36, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="5.56"/>
                    <measurement group_id="O2" value="3.47" spread="10.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis: C5 D1 (n=33, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="5.80"/>
                    <measurement group_id="O2" value="3.51" spread="12.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis: C6 D1 (n=29, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="13.64"/>
                    <measurement group_id="O2" value="3.03" spread="12.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis: C7 D1 (n=27, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="3.45" spread="10.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis: C8 D1 (n=22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="1.23" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" spread="11.78"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis: EOT (n=26, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="5.26" spread="16.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: Baseline (n=56, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.17" spread="20.60"/>
                    <measurement group_id="O2" value="31.42" spread="28.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C2 D1 (n=48, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.86" spread="25.23"/>
                    <measurement group_id="O2" value="23.90" spread="21.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C3 D1 (n=45, 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.83" spread="22.09"/>
                    <measurement group_id="O2" value="20.41" spread="18.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C4 D1 (n=36, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.10" spread="20.01"/>
                    <measurement group_id="O2" value="24.69" spread="21.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C5 D1 (n=33, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.30" spread="21.21"/>
                    <measurement group_id="O2" value="23.12" spread="19.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C6 D1 (n=28, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.32" spread="24.76"/>
                    <measurement group_id="O2" value="21.86" spread="18.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C7 D1 (n=27, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.45" spread="25.52"/>
                    <measurement group_id="O2" value="20.16" spread="16.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C8 D1 (n=22, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.75" spread="21.94"/>
                    <measurement group_id="O2" value="21.37" spread="16.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C9 D1 (n=18, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.78" spread="29.83"/>
                    <measurement group_id="O2" value="18.69" spread="14.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C10 D1 (n=17, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.76" spread="27.80"/>
                    <measurement group_id="O2" value="19.88" spread="15.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C11 D1 (n=15, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.41" spread="24.80"/>
                    <measurement group_id="O2" value="19.75" spread="15.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.33" spread="22.50"/>
                    <measurement group_id="O2" value="22.22" spread="19.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.50" spread="31.95"/>
                    <measurement group_id="O2" value="16.67" spread="16.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea: EOT (n=25, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.22" spread="23.33"/>
                    <measurement group_id="O2" value="33.63" spread="28.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Mouth: Baseline (n=56, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="12.19"/>
                    <measurement group_id="O2" value="1.15" spread="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Mouth: C2 D1 (n=51, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.95" spread="26.88"/>
                    <measurement group_id="O2" value="9.43" spread="23.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Mouth: C3 D1 (n=45, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.52" spread="28.03"/>
                    <measurement group_id="O2" value="9.22" spread="21.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Mouth: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.62" spread="31.64"/>
                    <measurement group_id="O2" value="8.33" spread="21.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Mouth: C5 D1 (n=33, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.23" spread="36.79"/>
                    <measurement group_id="O2" value="11.40" spread="23.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Mouth: C6 D1 (n=28, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="30.77"/>
                    <measurement group_id="O2" value="6.06" spread="19.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Mouth: C7 D1 (n=28, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.86" spread="27.94"/>
                    <measurement group_id="O2" value="6.90" spread="16.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Mouth: C8 D1 (n=22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="30.43"/>
                    <measurement group_id="O2" value="3.70" spread="10.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Mouth: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" spread="15.36"/>
                    <measurement group_id="O2" value="5.80" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Mouth: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.61" spread="33.46"/>
                    <measurement group_id="O2" value="10.00" spread="26.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Mouth: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.22" spread="37.09"/>
                    <measurement group_id="O2" value="8.77" spread="24.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Mouth: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="23.57"/>
                    <measurement group_id="O2" value="7.84" spread="18.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Mouth: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" spread="38.83"/>
                    <measurement group_id="O2" value="4.76" spread="12.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Mouth: EOT (n=26, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.97" spread="24.14"/>
                    <measurement group_id="O2" value="4.39" spread="13.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.55" spread="17.31"/>
                    <measurement group_id="O2" value="6.78" spread="14.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia: C2 D1 (n=51, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.76" spread="22.92"/>
                    <measurement group_id="O2" value="6.92" spread="17.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia: C3 D1 (n=46, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.77" spread="20.58"/>
                    <measurement group_id="O2" value="4.96" spread="11.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.91" spread="20.59"/>
                    <measurement group_id="O2" value="2.78" spread="9.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia: C5 D1 (n=32, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.50" spread="26.44"/>
                    <measurement group_id="O2" value="4.39" spread="11.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia: C6 D1 (n=28, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.10" spread="27.73"/>
                    <measurement group_id="O2" value="7.07" spread="16.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia: C7 D1 (n=28, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.90" spread="26.00"/>
                    <measurement group_id="O2" value="5.95" spread="15.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia: C8 D1 (n=22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="26.73"/>
                    <measurement group_id="O2" value="1.23" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" spread="15.36"/>
                    <measurement group_id="O2" value="1.45" spread="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.57" spread="26.20"/>
                    <measurement group_id="O2" value="6.67" spread="17.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.44" spread="29.46"/>
                    <measurement group_id="O2" value="1.75" spread="7.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" spread="14.05"/>
                    <measurement group_id="O2" value="3.92" spread="16.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.83" spread="24.80"/>
                    <measurement group_id="O2" value="4.76" spread="17.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia: EOT (n=26, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.69" spread="21.72"/>
                    <measurement group_id="O2" value="7.89" spread="19.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.52" spread="19.81"/>
                    <measurement group_id="O2" value="15.25" spread="26.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy: C2 D1 (n=51, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.84" spread="30.44"/>
                    <measurement group_id="O2" value="33.96" spread="33.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy: C3 D1 (n=46, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.68" spread="34.15"/>
                    <measurement group_id="O2" value="34.75" spread="36.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy: C4 D1 (n=37, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.05" spread="37.86"/>
                    <measurement group_id="O2" value="38.19" spread="32.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy: C5 D1 (n=33, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.51" spread="39.19"/>
                    <measurement group_id="O2" value="42.11" spread="33.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy: C6 D1 (n=29, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.17" spread="39.11"/>
                    <measurement group_id="O2" value="52.53" spread="33.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy: C7 D1 (n=28, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.81" spread="37.93"/>
                    <measurement group_id="O2" value="54.02" spread="33.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy: C8 D1 (n=22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.58" spread="40.08"/>
                    <measurement group_id="O2" value="50.62" spread="36.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy: C9 D1 (n=17, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.10" spread="40.73"/>
                    <measurement group_id="O2" value="56.52" spread="36.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.10" spread="42.40"/>
                    <measurement group_id="O2" value="48.33" spread="38.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy: C11 D1 (n=14, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00" spread="42.87"/>
                    <measurement group_id="O2" value="49.12" spread="35.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy: C12 D1 (n=9, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.56" spread="40.83"/>
                    <measurement group_id="O2" value="54.90" spread="38.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.33" spread="42.73"/>
                    <measurement group_id="O2" value="47.62" spread="38.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy: EOT (n=25, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.33" spread="35.12"/>
                    <measurement group_id="O2" value="40.35" spread="38.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="11.51"/>
                    <measurement group_id="O2" value="2.26" spread="10.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia: C2 D1 (n=50, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.33" spread="33.56"/>
                    <measurement group_id="O2" value="71.70" spread="32.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia: C3 D1 (n=46, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.91" spread="37.13"/>
                    <measurement group_id="O2" value="68.89" spread="38.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia: C4 D1 (n=37, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.77" spread="40.43"/>
                    <measurement group_id="O2" value="60.00" spread="42.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia: C5 D1 (n=33, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.62" spread="44.19"/>
                    <measurement group_id="O2" value="64.76" spread="44.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia: C6 D1 (n=28, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.05" spread="42.48"/>
                    <measurement group_id="O2" value="61.46" spread="45.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia: C7 D1 (n=28, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.29" spread="46.31"/>
                    <measurement group_id="O2" value="40.48" spread="45.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia: C8 D1 (n=21, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.86" spread="44.90"/>
                    <measurement group_id="O2" value="44.44" spread="48.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.78" spread="43.16"/>
                    <measurement group_id="O2" value="31.88" spread="44.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.37" spread="43.25"/>
                    <measurement group_id="O2" value="11.67" spread="29.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia: C11 D1 (n=14, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="36.40"/>
                    <measurement group_id="O2" value="16.67" spread="34.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33" spread="28.11"/>
                    <measurement group_id="O2" value="9.80" spread="28.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33" spread="23.57"/>
                    <measurement group_id="O2" value="7.14" spread="26.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia: EOT (n=26, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" spread="42.16"/>
                    <measurement group_id="O2" value="27.03" spread="39.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.81" spread="28.93"/>
                    <measurement group_id="O2" value="20.90" spread="25.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain: C2 D1 (n=51, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.95" spread="27.69"/>
                    <measurement group_id="O2" value="10.06" spread="18.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain: C3 D1 (n=45, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.81" spread="25.18"/>
                    <measurement group_id="O2" value="5.67" spread="12.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain: C4 D1 (n=36, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.81" spread="24.49"/>
                    <measurement group_id="O2" value="9.03" spread="19.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain: C5 D1 (n=33, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.11" spread="19.84"/>
                    <measurement group_id="O2" value="3.51" spread="10.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain: C6 D1 (n=28, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.48" spread="21.24"/>
                    <measurement group_id="O2" value="1.01" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain: C7 D1 (n=28, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.90" spread="18.62"/>
                    <measurement group_id="O2" value="3.57" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain: C8 D1 (n=22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.64" spread="16.77"/>
                    <measurement group_id="O2" value="3.70" spread="10.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.96" spread="20.26"/>
                    <measurement group_id="O2" value="7.25" spread="14.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.72" spread="16.91"/>
                    <measurement group_id="O2" value="8.33" spread="18.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain: C11 D1 (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.44" spread="29.46"/>
                    <measurement group_id="O2" value="7.02" spread="13.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain: C12 D1 (n=10, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33" spread="17.21"/>
                    <measurement group_id="O2" value="2.08" spread="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain: C13 D1 (n=7, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.05" spread="26.23"/>
                    <measurement group_id="O2" value="4.76" spread="12.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain: EOT (n=26, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.77" spread="33.89"/>
                    <measurement group_id="O2" value="15.31" spread="24.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm/shoulder pain: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.83" spread="27.39"/>
                    <measurement group_id="O2" value="20.34" spread="29.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm/shoulder pain: C2 D1 (n=51, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.91" spread="28.25"/>
                    <measurement group_id="O2" value="20.75" spread="24.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm/shoulder pain: C3 D1 (n=45, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.81" spread="25.18"/>
                    <measurement group_id="O2" value="5.67" spread="12.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm/shoulder pain: C4 D1 (n=37, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.92" spread="25.51"/>
                    <measurement group_id="O2" value="17.02" spread="30.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm/shoulder pain: C5 D1 (n=33, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.14" spread="26.39"/>
                    <measurement group_id="O2" value="14.91" spread="26.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm/shoulder pain: C6 D1 (n=29, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.09" spread="26.16"/>
                    <measurement group_id="O2" value="5.05" spread="12.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm/shoulder pain: C7 D1 (n=28, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.48" spread="23.10"/>
                    <measurement group_id="O2" value="14.94" spread="22.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm/shoulder pain: C8 D1 (n=22, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="26.73"/>
                    <measurement group_id="O2" value="14.10" spread="19.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm/shoulder pain: C9 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.81" spread="23.49"/>
                    <measurement group_id="O2" value="13.04" spread="19.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm/shoulder pain: C10 D1 (n=17, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.73" spread="23.74"/>
                    <measurement group_id="O2" value="20.00" spread="27.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm/shoulder pain: C11 D1 (n=14, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.19" spread="29.75"/>
                    <measurement group_id="O2" value="15.79" spread="23.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm/shoulder pain: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.33" spread="22.50"/>
                    <measurement group_id="O2" value="25.49" spread="32.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm/shoulder pain: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.83" spread="24.80"/>
                    <measurement group_id="O2" value="19.05" spread="25.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm/shoulder pain: EOT (n=26, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.80" spread="33.92"/>
                    <measurement group_id="O2" value="23.68" spread="31.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other pain: Baseline (n=52, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.85" spread="32.36"/>
                    <measurement group_id="O2" value="25.15" spread="34.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other pain: C2 D1 (n=49, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.53" spread="28.85"/>
                    <measurement group_id="O2" value="32.67" spread="31.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other pain: C3 D1 (n=46, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.06" spread="31.81"/>
                    <measurement group_id="O2" value="23.40" spread="31.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other pain: C4 D1 (n=36, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.93" spread="27.73"/>
                    <measurement group_id="O2" value="28.15" spread="30.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other pain: C5 D1 (n=32, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" spread="29.33"/>
                    <measurement group_id="O2" value="26.32" spread="33.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other pain: C6 D1 (n=28, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.76" spread="26.20"/>
                    <measurement group_id="O2" value="27.27" spread="33.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other pain: C7 D1 (n=28, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.14" spread="35.70"/>
                    <measurement group_id="O2" value="35.71" spread="36.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other pain: C8 D1 (n=22, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="28.64"/>
                    <measurement group_id="O2" value="25.64" spread="33.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other pain: C9 D1 (n=15, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.11" spread="34.43"/>
                    <measurement group_id="O2" value="31.88" spread="34.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other pain: C10 D1 (n=16, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" spread="28.55"/>
                    <measurement group_id="O2" value="22.81" spread="31.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other pain: C11 D1 (n=14, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.86" spread="33.15"/>
                    <measurement group_id="O2" value="25.93" spread="33.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other pain: C12 D1 (n=10, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" spread="27.22"/>
                    <measurement group_id="O2" value="27.45" spread="33.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other pain: C13 D1 (n=8, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.17" spread="27.82"/>
                    <measurement group_id="O2" value="26.19" spread="29.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other pain: EOT (n=25, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.67" spread="32.60"/>
                    <measurement group_id="O2" value="29.73" spread="36.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicine for pain: Baseline (n=37, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.36" spread="29.23"/>
                    <measurement group_id="O2" value="66.67" spread="28.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicine for pain: C3 D1 (n=29, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.52" spread="31.48"/>
                    <measurement group_id="O2" value="68.06" spread="31.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicine for pain: C4 D1 (n=19, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.16" spread="26.98"/>
                    <measurement group_id="O2" value="72.41" spread="23.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicine for pain: C5 D1 (n=17, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.59" spread="26.04"/>
                    <measurement group_id="O2" value="72.73" spread="22.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicine for pain: C6 D1 (n=16, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" spread="29.81"/>
                    <measurement group_id="O2" value="72.55" spread="24.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicine for pain: C7 D1 (n=15, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.56" spread="26.63"/>
                    <measurement group_id="O2" value="66.67" spread="29.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicine for pain: C8 D1 (n=13, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" spread="27.22"/>
                    <measurement group_id="O2" value="75.00" spread="25.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicine for pain: C9 D1 (n=6, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.23" spread="13.61"/>
                    <measurement group_id="O2" value="69.05" spread="20.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicine for pain: C10 D1 (n=10, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.34" spread="14.05"/>
                    <measurement group_id="O2" value="60.00" spread="26.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicine for pain: C11 D1 (n=9, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.15" spread="17.57"/>
                    <measurement group_id="O2" value="81.48" spread="17.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicine for pain: C12 D1 (n=6, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.56" spread="17.22"/>
                    <measurement group_id="O2" value="70.37" spread="20.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicine for pain: C13 D1 (n=0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not analyzed as no participants were evaluable for the particular cycle.</measurement>
                    <measurement group_id="O2" value="NA">Data was not analyzed as no participants were evaluable for the particular cycle.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicine for pain: EOT (n=15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00" spread="22.54"/>
                    <measurement group_id="O2" value="66.67" spread="29.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicine for pain: C2 D1 (n=30, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.22" spread="22.72"/>
                    <measurement group_id="O2" value="71.43" spread="26.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants by Ribonucleic Acid (RNA) Expression Profile in Whole Blood</title>
        <description>RNA expression profiles of genes which were associated with tumor growth, angiogenesis and metastases were collected and correlated with efficacy.</description>
        <time_frame>Baseline, C1 D1, C1 D15, C2 D1, C3 D1, C4 D1 and C5 D1</time_frame>
        <population>Data was not generated but sample was collected for banking and moved to a separate exploratory research database for future research.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib + Paclitaxel + Carboplatin</title>
            <description>Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m^2) over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + Paclitaxel + Carboplatin</title>
            <description>Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m^2 over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants by Ribonucleic Acid (RNA) Expression Profile in Whole Blood</title>
          <description>RNA expression profiles of genes which were associated with tumor growth, angiogenesis and metastases were collected and correlated with efficacy.</description>
          <population>Data was not generated but sample was collected for banking and moved to a separate exploratory research database for future research.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Circulating Endothelial Cells (CEC) in Blood: Total CEC</title>
        <description>Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.</description>
        <time_frame>Baseline (C1 D1), C1 D15, C2 D1, C3 D1, C4 D1, C5 D1, C7 D1, C9 D1 and C11 D1</time_frame>
        <population>ITT population: participants randomized with study drug designated according to initial randomization, regardless of whether participants received study drug or different drug. ânâ: participants evaluated at specific time point for each group respectively. âNâ (Number of participants analyzed) signifies participants evaluable for the measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib + Paclitaxel + Carboplatin</title>
            <description>Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m^2) over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + Paclitaxel + Carboplatin</title>
            <description>Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m^2 over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Circulating Endothelial Cells (CEC) in Blood: Total CEC</title>
          <description>Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.</description>
          <population>ITT population: participants randomized with study drug designated according to initial randomization, regardless of whether participants received study drug or different drug. ânâ: participants evaluated at specific time point for each group respectively. âNâ (Number of participants analyzed) signifies participants evaluable for the measure.</population>
          <units>Cells/milliliter (cells/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=39, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46815.38" spread="131531.755"/>
                    <measurement group_id="O2" value="16960.41" spread="25527.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1 D15 (n=27, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11780.15" spread="13127.847"/>
                    <measurement group_id="O2" value="21882.41" spread="67578.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (n=32, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29229.09" spread="55724.997"/>
                    <measurement group_id="O2" value="40507.36" spread="82161.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (n=24, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19517.50" spread="19793.722"/>
                    <measurement group_id="O2" value="25215.70" spread="42932.747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (n=20, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24556.05" spread="22434.011"/>
                    <measurement group_id="O2" value="41944.59" spread="70239.938"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28266.22" spread="39480.209"/>
                    <measurement group_id="O2" value="37468.13" spread="82647.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (n=11, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71770.91" spread="94182.032"/>
                    <measurement group_id="O2" value="36964.36" spread="60577.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (n=7, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58680.00" spread="78138.794"/>
                    <measurement group_id="O2" value="107978.14" spread="206314.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (n=6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116620.83" spread="129577.280"/>
                    <measurement group_id="O2" value="120847.67" spread="140674.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Circulating Endothelial Cells (CEC) in Blood</title>
        <description>Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.</description>
        <time_frame>Baseline (C1 D1), C1 D15, C2 D1, C3 D1, C4 D1, C5 D1, C7 D1, C9 D1 and C11 D1</time_frame>
        <population>ITT population: participants randomized with study drug designated according to initial randomization, regardless of whether participants received study drug or different drug. ânâ: participants evaluated at specific time point for each group respectively. âNâ (Number of participants analyzed) signifies participants evaluable for the measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib + Paclitaxel + Carboplatin</title>
            <description>Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m^2) over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + Paclitaxel + Carboplatin</title>
            <description>Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m^2 over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Circulating Endothelial Cells (CEC) in Blood</title>
          <description>Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.</description>
          <population>ITT population: participants randomized with study drug designated according to initial randomization, regardless of whether participants received study drug or different drug. ânâ: participants evaluated at specific time point for each group respectively. âNâ (Number of participants analyzed) signifies participants evaluable for the measure.</population>
          <units>Flourescent Intensity Unit (FIU)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pVEGFR2+) (n=50, 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1936317.98" spread="1252665.900"/>
                    <measurement group_id="O2" value="1764577.67" spread="1331540.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1 D15 (pVEGFR2+) (n=38, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1822095.74" spread="1678888.153"/>
                    <measurement group_id="O2" value="1810049.32" spread="1330590.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (pVEGFR2+) (n=41, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1767065.44" spread="1442193.213"/>
                    <measurement group_id="O2" value="2090673.60" spread="1659128.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (pVEGFR2+) (n=33, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1715569.39" spread="1515661.662"/>
                    <measurement group_id="O2" value="1578940.53" spread="1274415.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (pVEGFR2+) (n=25, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1472447.68" spread="970463.341"/>
                    <measurement group_id="O2" value="1815402.16" spread="1263516.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (pVEGFR2+) (n=24, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2208801.96" spread="3098289.400"/>
                    <measurement group_id="O2" value="1794843.58" spread="1458412.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (pVEGFR2+) (n=16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1405048.00" spread="879770.893"/>
                    <measurement group_id="O2" value="1634128.00" spread="1443612.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (pVEGFR2+) (n=12, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2280989.75" spread="1050678.808"/>
                    <measurement group_id="O2" value="2283985.00" spread="1093158.760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (pVEGFR2+) (n=10, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1828224.90" spread="1179020.490"/>
                    <measurement group_id="O2" value="2354939.11" spread="1116283.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (VEGFR2+) (n=50, 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1694522.56" spread="1534520.504"/>
                    <measurement group_id="O2" value="1841618.36" spread="1300088.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1 D15 (VEGFR2+) (n=38, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1634956.89" spread="1285333.248"/>
                    <measurement group_id="O2" value="1740268.05" spread="1444881.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (VEGFR2+) (n=41, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1597041.59" spread="865675.123"/>
                    <measurement group_id="O2" value="1444404.94" spread="1097875.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (VEGFR2+) (n=33, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1443986.61" spread="843071.909"/>
                    <measurement group_id="O2" value="1504595.71" spread="1163469.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (VEGFR2+) (n=25, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1181666.88" spread="673860.407"/>
                    <measurement group_id="O2" value="1259913.44" spread="765707.741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (VEGFR2+) (n=24, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1371956.00" spread="948166.942"/>
                    <measurement group_id="O2" value="1447188.88" spread="885864.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (VEGFR2+) (n=16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1028231.44" spread="495059.378"/>
                    <measurement group_id="O2" value="1317560.13" spread="720095.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (VEGFR2+) (n=12, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1485819.58" spread="953884.288"/>
                    <measurement group_id="O2" value="1476621.00" spread="1688887.819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (VEGFR2+) (n=10, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1573298.80" spread="1152155.993"/>
                    <measurement group_id="O2" value="1332064.78" spread="668964.428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (pPDGFRB+) (n=50, 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1646702.34" spread="1482336.244"/>
                    <measurement group_id="O2" value="1734853.24" spread="1485338.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1 D15 (pPDGFRB+) (n=38, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1253893.97" spread="894629.298"/>
                    <measurement group_id="O2" value="1599671.65" spread="1669690.889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (pPDGFRB+) (n=41, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1395311.88" spread="1111766.454"/>
                    <measurement group_id="O2" value="1885684.31" spread="1356916.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (pPDGFRB+) (n=33, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1470448.94" spread="841336.398"/>
                    <measurement group_id="O2" value="1285439.44" spread="1083860.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (pPDGFRB+) (n=25, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1046445.72" spread="588769.375"/>
                    <measurement group_id="O2" value="1514713.97" spread="1150805.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (pPDGFRB+) (n=24, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2253114.67" spread="3314986.569"/>
                    <measurement group_id="O2" value="2299459.38" spread="5140939.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (pPDGFRB+) (n=16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1380133.19" spread="1002147.826"/>
                    <measurement group_id="O2" value="2163313.88" spread="3720352.717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (pPDGFRB+) (n=12, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2172539.75" spread="2323386.087"/>
                    <measurement group_id="O2" value="2225289.18" spread="1126401.528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (pPDGFRB+) (n=10, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1580028.90" spread="927582.364"/>
                    <measurement group_id="O2" value="3127640.22" spread="2817719.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (PDGFRB+) (n=50, 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1775826.12" spread="1485762.540"/>
                    <measurement group_id="O2" value="3176459.69" spread="3222201.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1 D15 (PDGFRB+) (n=38, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1589914.37" spread="985828.939"/>
                    <measurement group_id="O2" value="1819988.05" spread="1807664.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (PDGFRB+) (n=41, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1840677.73" spread="1315688.806"/>
                    <measurement group_id="O2" value="1586256.17" spread="1092406.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (PDGFRB+) (n=33, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1690163.33" spread="1064816.034"/>
                    <measurement group_id="O2" value="1518360.71" spread="1286285.813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (PDGFRB+) (n=25, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1288624.64" spread="641546.254"/>
                    <measurement group_id="O2" value="1408366.91" spread="1013859.813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (PDGFRB+) (n=24, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1309639.50" spread="975890.557"/>
                    <measurement group_id="O2" value="1364500.50" spread="1058758.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (PDGFRB+) (n=16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1049351.00" spread="587546.139"/>
                    <measurement group_id="O2" value="1287039.25" spread="922009.811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (PDGFRB+) (n=12, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1666413.67" spread="1465165.325"/>
                    <measurement group_id="O2" value="1625161.64" spread="1467355.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (PDGFRB+) (n=10, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1533606.00" spread="1258733.501"/>
                    <measurement group_id="O2" value="1959067.11" spread="1973194.943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Soluble Proteins</title>
        <description>Plasma concentrations of soluble proteins (soluble- stem-cell factor receptor (sKIT) vascular endothelial growth factor [VEGF], and vascular endothelial growth factor receptor-2 [VEGFR2], VEGFR3) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.</description>
        <time_frame>Baseline, C1D1, C1D15, C2D1, C3D1, C4D1, C5D1, C7D1, C9D1 and C11D1</time_frame>
        <population>ITT population: participants randomized with study drug designated according to initial randomization, regardless of whether participants received study drug or different drug. ânâ: participants evaluated at specific time point for each group respectively. âNâ (Number of participants analyzed) signifies participants evaluable for the measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib + Paclitaxel + Carboplatin</title>
            <description>Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m^2) over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + Paclitaxel + Carboplatin</title>
            <description>Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m^2 over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Soluble Proteins</title>
          <description>Plasma concentrations of soluble proteins (soluble- stem-cell factor receptor (sKIT) vascular endothelial growth factor [VEGF], and vascular endothelial growth factor receptor-2 [VEGFR2], VEGFR3) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.</description>
          <population>ITT population: participants randomized with study drug designated according to initial randomization, regardless of whether participants received study drug or different drug. ânâ: participants evaluated at specific time point for each group respectively. âNâ (Number of participants analyzed) signifies participants evaluable for the measure.</population>
          <units>Picogram/mL (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (SKIT) (n=52, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49740.29" spread="16998.69"/>
                    <measurement group_id="O2" value="49544.15" spread="14803.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1 D15 (SKIT) (n=42, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53095.48" spread="18233.85"/>
                    <measurement group_id="O2" value="55801.39" spread="22058.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (SKIT) (n=41, 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52979.39" spread="18018.73"/>
                    <measurement group_id="O2" value="55729.65" spread="21476.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (SKIT) (n=40, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53817.75" spread="19638.72"/>
                    <measurement group_id="O2" value="65634.14" spread="27097.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (SKIT) (n=32, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56961.41" spread="20828.07"/>
                    <measurement group_id="O2" value="72671.32" spread="33207.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (SKIT) (n=27, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58305.00" spread="20311.85"/>
                    <measurement group_id="O2" value="68677.21" spread="30073.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (SKIT) (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50701.11" spread="17927.98"/>
                    <measurement group_id="O2" value="75547.61" spread="24458.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (SKIT) (n=12, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48680.42" spread="14791.32"/>
                    <measurement group_id="O2" value="65990.78" spread="17003.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (SKIT) (n=11, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49251.82" spread="19469.45"/>
                    <measurement group_id="O2" value="66920.38" spread="12261.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (VEGF) (n=50, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.14" spread="66.60"/>
                    <measurement group_id="O2" value="121.83" spread="141.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1 D15 (VEGF) (n=40, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.08" spread="98.05"/>
                    <measurement group_id="O2" value="287.19" spread="171.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (VEGF) (n=39, 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.46" spread="128.06"/>
                    <measurement group_id="O2" value="324.33" spread="153.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (VEGF) (n=39, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.06" spread="159.80"/>
                    <measurement group_id="O2" value="368.23" spread="151.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (VEGF) (n=30, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.16" spread="282.49"/>
                    <measurement group_id="O2" value="405.13" spread="173.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (VEGF) (n=25, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.77" spread="175.32"/>
                    <measurement group_id="O2" value="400.16" spread="165.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (VEGF) (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226.62" spread="202.53"/>
                    <measurement group_id="O2" value="433.30" spread="172.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (VEGF) (n=12, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273.17" spread="207.22"/>
                    <measurement group_id="O2" value="422.38" spread="157.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (VEGF) (n=11, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339.86" spread="303.71"/>
                    <measurement group_id="O2" value="449.92" spread="144.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (VEGFR2) (n=52, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9587.31" spread="1570.27"/>
                    <measurement group_id="O2" value="9995.00" spread="2185.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1 D15 (VEGFR2) (n=42, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7828.10" spread="1959.39"/>
                    <measurement group_id="O2" value="10781.35" spread="2311.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (VEGFR2) (n=41, 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7477.80" spread="2146.89"/>
                    <measurement group_id="O2" value="10330.00" spread="2511.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (VEGFR2) (n=40, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7058.50" spread="2037.12"/>
                    <measurement group_id="O2" value="10129.47" spread="2244.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (VEGFR2) (n=32, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6885.94" spread="1754.19"/>
                    <measurement group_id="O2" value="9934.21" spread="1785.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (VEGFR2) (n=27, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6565.93" spread="1755.75"/>
                    <measurement group_id="O2" value="10140.59" spread="2056.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (VEGFR2) (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6401.11" spread="2360.24"/>
                    <measurement group_id="O2" value="10339.57" spread="1897.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (VEGFR2) (n=12, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6291.67" spread="2235.24"/>
                    <measurement group_id="O2" value="9421.25" spread="2446.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (VEGFR2) (n=11, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5696.36" spread="2724.57"/>
                    <measurement group_id="O2" value="9222.31" spread="2727.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (VEGFR3) (n=52, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44390.77" spread="75118.17"/>
                    <measurement group_id="O2" value="24718.33" spread="12494.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1 D15 (VEGFR3) (n=42, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33684.29" spread="52617.02"/>
                    <measurement group_id="O2" value="17693.51" spread="9679.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (VEGFR3) (n=41, 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35780.49" spread="68287.68"/>
                    <measurement group_id="O2" value="17798.37" spread="9710.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (VEGFR3) (n=40, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34147.00" spread="74220.30"/>
                    <measurement group_id="O2" value="15901.32" spread="8062.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (VEGFR3) (n=32, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19730.94" spread="9237.69"/>
                    <measurement group_id="O2" value="16307.37" spread="7409.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (VEGFR3) (n=27, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17452.59" spread="8614.99"/>
                    <measurement group_id="O2" value="16381.47" spread="6707.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (VEGFR3) (n=18, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17896.67" spread="8360.82"/>
                    <measurement group_id="O2" value="15626.30" spread="8873.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (VEGFR3) (n=12, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21449.17" spread="12806.75"/>
                    <measurement group_id="O2" value="14733.44" spread="6441.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (VEGFR3) (n=11, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22332.73" spread="12408.37"/>
                    <measurement group_id="O2" value="16048.46" spread="7064.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Plasma Concentration Change in the Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) Genotype</title>
        <description>UGT1A1 an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites.</description>
        <time_frame>Baseline (Day 1 of Cycle 1)</time_frame>
        <population>Data was reported in listings but not summarized due to statistical constraints.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib + Paclitaxel + Carboplatin</title>
            <description>Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m^2) over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive Axitinib (AG-013736) BID maintenance therapy.</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab+ Paclitaxel + Carboplatin</title>
            <description>Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m^2) over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive Axitinib (AG-013736) BID maintenance therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration Change in the Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) Genotype</title>
          <description>UGT1A1 an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites.</description>
          <population>Data was reported in listings but not summarized due to statistical constraints.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Axitinib + Paclitaxel + Carboplatin</title>
          <description>Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m^2) over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy.</description>
        </group>
        <group group_id="E2">
          <title>Bevacizumab + Paclitaxel + Carboplatin</title>
          <description>Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m^2 over 3 hours and carboplatin AUC of 6 mg*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Meningeal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

